Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2024, Vol. 56 ›› Issue (4): 729-734. doi: 10.19723/j.issn.1671-167X.2024.04.029

Previous Articles     Next Articles

Application value of anti-carbamylated protein antibody in the diagnosis of rheumatoid arthritis

Zhengfang LI,Cainan LUO,Lijun WU*(),Xue WU,Xinyan MENG,Xiaomei CHEN,Yamei SHI,Yan ZHONG   

  1. Department of Rheumatology and Immunology, People' s Hospital of Xinjiang Uygur Autonomous Region; Xinjiang Clinical Research Center for Rheumatoid Arthritis, Urumqi 830001, China
  • Received:2021-05-08 Online:2024-08-18 Published:2024-07-23
  • Contact: Lijun WU E-mail:wwlj330@126.com
  • Supported by:
    Key Research and Development Project of Xinjiang Autonomous Region(2022B03002-1)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To investigate the expression level and application value of anti-carbamylated protein (CarP) antibody in rheumatoid arthritis (RA). Methods: Demographic data and laboratory test results of RA patients, non-RA patients and healthy controls in the physical examination center were reviewed from December 2018 to June 2019 in the Rheumatology and Immunology Department of the People' s Hospital of Xinjiang Uygur Autonomous Region. The serum concentrations of anti-CarP antibodies in all the subjects were measured by ELISA and statistically analyzed. Results: A total of 259 subjects were included in this study, including 158 in the RA group (45 serum-negative RA patients), 59 in the non-RA group and 42 in the healthy control group. The concentration of anti-CarP antibody in RA group [8.31 (5.22, 15.26) U/mL] was higher than that in non-RA group [4.50 (3.35, 5.89) U/mL] and healthy control group [3.46 (2.76, 4.92) U/mL]. The concentration of anti-CarP antibody in non-RA group was not significantly different from that in healthy control group (P=0.10). Receiver operating characteristic (ROC) curve analysis showed that the sensitivity of anti-CarP antibody in the diagnosis of RA was 58.2%, and the specificity was 93.1%. The sensitivity of the combined detection of anti-CarP antibody, anti-cyclic peptide containing citrulline (CCP) antibody and rheumatoid factor (RF) was 82.3%, and the specificity was 96.5%. The positive rate of anti-CarP antibody in serum-negative RA patients was 44.4% (20/45). Univariate Logisitic regression analysis showed that age, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), RF, glucose-6-phosphate isomerase (GPI), anti-CCP antibody and anti-CarP antibody were risk factors for RA. Multivariate Logisitic regression analysis showed that anti-CCP antibody and anti-CarP antibody were independent risk factors for RA. Spearman correlation analysis showed that there was no significant correlation between anti-CarP antibody and swollen joint count (SJC), tenderness joints count (TJC), ESR, disease activity score for 28 joints (DAS28), clinical disease activity index (CDAI), simplified disease activity index (SDAI). The concentration of anti-CarP antibody in RA with bone erosion (n=88) was higher than that in RA without bone erosion (n=70), and there was significant difference between the two groups (P < 0.05). Conclusions: Anti-CarP antibody is an effective serological marker for the diagnosis of RA. The combined detection of RF, anti-CCP antibody and anti-CarP antibody can improve its diagnostic value, and anti-CarP antibody may be an effective assistant diagnostic tool for serum negative RA. The high serum concentration of anti-CarP antibody in patients with RA may indicate an increased risk of bone erosion and should be treated early, but further cohort studies are needed for follow-up observation.

Key words: Arthritis, rheumatoid, Autoantibodies, Diagnosis, Anti-carbamylated protein antibody

CLC Number: 

  • R593.22

Figure 1

Concentration of anti-CarP antibody in RA, non-RA and health control Anti-CarP, anti-carbamylated protein antibody; RA, rheumatoid arthritis; HC, health control."

Figure 2

ROC curve of anti-CarP antibody, RF and anti-CCP antibody in RA diagnosis Anti-CarP, anti-carbamylated protein antibody; RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinate peptide antibody."

Table 1

The characteristic value of ROC curve detected by anti-CarP antibody, anti-CCP antibody and RF alone or in combination"

Items AUC 95%CI Sensitivity/% Specificity/% P
Anti-CarP 0.81 0.76-0.86 58.2 93.1 <0.001
Anti-CCP 0.84 0.79-0.89 71.5 96.0 < 0.001
RF 0.74 0.68-0.79 63.9 85.1 < 0.001
RF+Anti-CCP 0.81 0.76-0.86 71.5 96.0 < 0.01
Anti-CarP+RF 0.86 0.81-0.90 81.0 73.3 < 0.01
Anti-CarP+Anti-CCP 0.91 0.87-0.94 82.3 94.1 < 0.01
Anti-CarP+Anti-CCP+RF 0.92 0.88-0.95 82.3 96.5 < 0.01

Table 2

Logistic regression analysis of the factors related to RA occurrence"

Items OR (95%CI) P
Age 1.020 (1.001-1.039) 0.043
CRP 1.055 (1.028-1.082) < 0.001
ESR 1.059 (1.040-1.078) < 0.001
RF 1.014 (1.007-1.020) < 0.001
GPI 2.776 (1.444-5.336) 0.002
Anti-CarP 1.022 (1.011-1.033) < 0.001
Anti-CCP 1.489 (1.308-1.696) < 0.001

Table 3

Correlation analysis between anti-CarP antibody and disease activity"

Disease activity indicators r P
SJC 0.06 0.45
TJC 0.06 0.49
CRP 0.24 0.00
ESR 0.09 0.24
DAS28-ESR 0.08 0.33
DAS28-CRP 0.13 0.12
CDAI 0.06 0.45
SDAI 0.09 0.28

Table 4

Comparison of clinical characteristics of RA patients with or without bone erosion"

Items Without bone erosion (n=70) With bone erosion (n=88) Statistics P
Female, n(%) 51 (72.80) 74 (84.10) 2.98 0.08
Age/years, $\bar x \pm s$ 45.63±12.36 55.64±11.47 -5.26 < 0.01
Course of the disease/months, M(P25, P75) 7.0 (3.0, 16.5) 36.0 (8.0, 120.0) -5.67 < 0.01
BMI/(kg/m2), $\bar x \pm s$ 23.28±3.11 24.02±4.22 -1.17 0.24
ESR/(mm/h), $\bar x \pm s$ 37.00 ±21.47 41.66±21.29 -1.36 0.17
CRP/(mg/L), M(P25, P75) 6.45 (2.50, 26.70) 9.05 (3.20, 31.07) -1.28 0.19
DAS28-ESR, $\bar x \pm s$ 4.54±1.30 4.71±1.26 -0.85 0.39
DAS28-CRP, $\bar x \pm s$ 3.95±1.29 4.08±1.24 -0.64 0.52
Anti-CarP/(U/mL), M(P25, P75) 7.66 (4.95, 12.75) 9.39 (5.65, 17.35) -2.06 0.03
1 Smolen JS , Aletaha D , McInnes IB . Rheumatoid arthritis[J]. Lancet, 2016, 388 (10055): 2023- 2038.
doi: 10.1016/S0140-6736(16)30173-8
2 Aletaha D , Neogi T , Silman AJ , et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Ann Rheum Dis, 2010, 69 (9): 1580- 1588.
doi: 10.1136/ard.2010.138461
3 Shi J , Knevel R , Suwannalai P , et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage[J]. Proc Natl Acad Sci USA, 2011, 108 (42): 17372- 17377.
doi: 10.1073/pnas.1114465108
4 Trouw LA , Mahler M . Closing the serological gap: Promising novel biomarkers for the early diagnosis of rheumatoid arthritis[J]. Autoimmun Rev, 2012, 12 (2): 318- 322.
doi: 10.1016/j.autrev.2012.05.007
5 Pratt AG , Isaacs JD . Seronegative rheumatoid arthritis: Pathogenetic and therapeutic aspects[J]. Best Pract Res Clin Rheumatol, 2014, 28 (4): 651- 659.
doi: 10.1016/j.berh.2014.10.016
6 Altman R , Alarcón G , Appelrouth D , et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand[J]. Arthritis Rheum, 1990, 33 (11): 1601- 1610.
doi: 10.1002/art.1780331101
7 Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997, 40 (9): 1725.
8 van der Linden S , Valkenburg HA , Cats A . Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria[J]. Arthritis Rheum, 1984, 27 (4): 361- 368.
doi: 10.1002/art.1780270401
9 Mosca M , Neri R , Bombardieri S . Undifferentiated connective tissue diseases (UCTD): A review of the literature and a proposal for preliminary classification criteria[J]. Clin Exp Rheumatol, 1999, 17 (5): 615- 620.
10 Cross M , Smith E , Hoy D , et al. The global burden of rheumatoid arthritis: Estimates from the global burden of disease 2010 study[J]. Ann Rheum Dis, 2014, 73 (7): 1316- 1322.
doi: 10.1136/annrheumdis-2013-204627
11 Kitas GD , Gabriel SE . Cardiovascular disease in rheumatoid arthritis: State of the art and future perspectives[J]. Ann Rheum Dis, 2011, 70 (1): 8- 14.
doi: 10.1136/ard.2010.142133
12 Sokka T , Kautiainen H , et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: Data from 32 countries in the QUEST-RA study[J]. Arthritis Res Ther, 2010, 12 (2): R42.
doi: 10.1186/ar2951
13 Myasoedova E , Davis J , Matteson E , et al. Is the epidemiology of rheumatoid arthritis changing results from a population-based incidence study, 1985-2014[J]. Ann Rheum Dis, 2020, 79 (4): 440- 444.
doi: 10.1136/annrheumdis-2019-216694
14 郑晓, 王玉梅, 刘秀梅. 抗氨甲酰化蛋白抗体对类风湿关节炎的诊断价值[J]. 中华临床医师杂志(电子版), 2017, 11 (4): 570- 573.
doi: 10.3877/cma.j.issn.1674-0785.2017.04.008
15 Pecani A , Alessandri C , Spinelli FR , et al. Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases[J]. Arthritis Res Ther, 2016, 18 (1): 276.
doi: 10.1186/s13075-016-1173-0
16 Othman MA , Ghazali WSW , Hamid WZWA , et al. Anti-carbamylated protein antibodies in rheumatoid arthritis patients and their association with rheumatoid factor[J]. Saudi Med J, 2017, 38 (9): 934- 941.
doi: 10.15537/smj.2017.9.20841
17 罗云霞. 评价抗CarP抗体在RA患者中的临床诊断价值[D]. 银川: 宁夏医科大学, 2018.
18 Brink M , Verheul MK , Rönnelid J , et al. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibo-dies and association with radiological damage[J]. Arthritis Res Ther, 2015, 17 (1): 25.
doi: 10.1186/s13075-015-0536-2
19 Kumar S , Pangtey G , Gupta R , et al. Assessment of anti-CarP antibodies, disease activity and quality of life in rheumatoid arthritis patients on conventional and biological disease: Modifying antirheumatic drugs[J]. Reumatologia, 2017, 55 (1): 4- 9.
20 Humphreys JH , Verheul MK , Barton A , et al. Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: Results from the Norfolk Arthritis Register[J]. Ann Rheum Dis, 2016, 75 (6): 1139- 1144.
doi: 10.1136/annrheumdis-2015-207326
21 Truchetet ME , Dublanc S , Barnetche T , et al. Anti-carbamylated protein antibodies presence in early arthritis with a poorer clinical and radiological outcome: Data from the French ESPOIR cohort[J]. Arthritis Rheumatol, 2017, 69 (12): 2292- 2302.
doi: 10.1002/art.40237
[1] Ye ZHAO, Xiaoli DIAO, Yan XIONG. Application of cell transfer technology in pathological diagnosis of micro-volume cell fluid [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 208-213.
[2] Yue WANG, Yuhong LIANG. Florid cemento-osseous dysplasia: A case report [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 220-224.
[3] Yanting CHI, Hongjie JIANG, Yan CHEN, Zhixiu XU, Binbin LI. Value of direct immunofluorescence in the diagnosis of oral mucosal pemphigus vulgaris: A retrospective study based on multi-index combined analysis [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 68-73.
[4] Jingyan GU, Xinyi LI, Jinxia ZHAO, Rong MU. Diabetic Charcot neuroarthropathy initially misdiagnosed as rheumatoid arthritis and gout: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1193-1197.
[5] Xiaodi XIAO, Youchen XIA, Jianying LIU, Peng FU. Left sided sternocleidomastoid interosseous intravascular papillary endothelial hyperplasia: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 1002-1004.
[6] Xiangyu SUN, Chao YUAN, Xinzhu ZHOU, Jing DIAO, Shuguo ZHENG. Application of salivary micro-ecosystem in early prevention and control of oral and systemic diseases [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 859-863.
[7] Zhao CHEN, Yongkang QIU, Lei KANG. Classical Sweet syndrome with multiple organ lesions by 18F-FDG PET/CT: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(2): 403-407.
[8] Guangyan YU, Xin PENG, Min GAO, Peng YE, Na GE, Mengqi JIA, Bingyu LI, Zunan TANG, Leihao HU, Wenbo ZHANG. Research progress in diagnosis and treatment of salivary gland tumors [J]. Journal of Peking University (Health Sciences), 2025, 57(1): 1-6.
[9] Yuanyuan FANG, Fan XU, Jie LEI, Hao ZHANG, Wenyu ZHANG, Yu SUN, Hongxin WU, Kaiyuan FU, Weiyu MAO. Development and validation of a clinical automatic diagnosis system based on diagnostic criteria for temporomandibular disorders [J]. Journal of Peking University (Health Sciences), 2025, 57(1): 192-201.
[10] Jialu CHE, Zichen LIU, Kun LI, Chen ZHANG, Nanying CHE. Clinical value of automated EasyNAT system for the diagnosis of tuberculosis in paraffin-embedded tissues [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1047-1051.
[11] Xinxin CHEN, Zhe TANG, Yanchun QIAO, Wensheng RONG. Caries experience and its correlation with caries activity of 4-year-old children in Miyun District of Beijing [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 833-838.
[12] Hua ZHONG, Yuan LI, Liling XU, Mingxin BAI, Yin SU. Application of 18F-FDG PET/CT in rheumatic diseases [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 853-859.
[13] Zhanhong LAI,Jiachen LI,Zelin YUN,Yonggang ZHANG,Hao ZHANG,Xiaoyan XING,Miao SHAO,Yuebo JIN,Naidi WANG,Yimin LI,Yuhui LI,Zhanguo LI. A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 284-292.
[14] Yan-hong MENG,Yi-fan CHEN,Pei-ru ZHOU. Clinical and immunological features of primary Sjögren's syndrome patients with positive anti-centromere protein B antibody [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1088-1096.
[15] Hai-hong YAO,Fan YANG,Su-mei TANG,Xia ZHANG,Jing HE,Yuan JIA. Clinical characteristics and diagnostic indicators of macrophage activation syndrome in patients with systemic lupus erythematosus and adult-onset Still's disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 966-974.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd